Since c-Myc protein degradation is mainly regulated by the ubiquitin–proteasome pathway,17 it was investigated whether USP34 regulates c-Myc stability through the proteasome pathway by treating HCC cells with MG132 (a proteasome inhibitor). Here, MYC is linked to hepatocellular carcinoma.